International Stem Cell Corporation, Through Its Subsidiary Lifeline Cell Technology, Announces the Launch and Sale of New Products into the Human Cell Research Market

International Stem Cell Corporation (OTCBB:ISCO) (www.internationalstemcell.com), announces that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human "parthenogenetic" stem cells from unfertilized eggs. Parthenogenetic stem cells not only solve ethical problems, but also promise to minimize immune-rejection by providing cells that can be immune-matched to large segments of the population.

These products represent milestone achievements in ISCO's strategy of generating revenue from the sale of research products, while building infrastructure from that effort to expand the manufacturing and quality control capacities ISCO needs to commercialize the therapeutic applications of human parthenogenetic stem cells.

One of its newest and most promising products consist of "xeno-free" human cells and culture reagents that allow researchers to study embryonic stem cells without contamination from animal (non-human) components. These products meet the needs for stem cell research to be done using "human-only" systems. Other products include Lifeline's living human cells and reagents for research and drug development into cardiovascular, kidney, lung, nerve, eye and skin disease. Lifeline is continuing to develop unique reagents and media for the growing field of stem cell research. The "Lifeline" brand of products consist of human cells and the culture reagents and growth factors needed to grow the cells.

According to Jeffrey Janus, CEO of Lifeline, "We are proud of the quality of our new products, as reflected in the sales growth they are exhibiting in the human cell research markets. We look forward to launching more new products into the growing markets for stem cell research and drug development. These products will contribute to the success of ISCO, not only by supporting ISCO's therapeutic research, but also through the development of critical manufacturing and quality control systems necessary for ISCO to produce therapeutic human cells in the future."

Lifeline's products can be found at www.lifelinecelltechnology.com.

For more news and information on International Stem Cell Corporation please visit www.IRGnews.com/coi/ISCO where you can find the CEO's video, a fact sheet on the company, investor presentations, and more.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California biotechnology company focused on developing therapeutic and research products. ISCO's technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will minimize immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true "Stem Cell Bank" and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at: www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS:

Statements pertaining to anticipated future financial and/or operating results, future growth in research, technology, clinical development and potential joint venture and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Cornea, Parthenogenesis

SOURCE: International Stem Cell Corporation

International Stem Cell Corporation 
Kenneth C. Aldrich, Chairman, CEO 
760-940-6383 
kaldrich@intlstemcell.com 
or 
Lifeline Cell Technology 
Jeffrey Janus, CEO 
janusj@lifelinecelltech.com 
or 
The Investor Relations Group 
Laura Colontrelle 
212-825-3210 
lcolontrelle@investorrelationsgroup.com

Related terms: animal, bank, biotechnology, business, california, cardiovascular, ceo, clinical, communications, contamination, corporate, joint venture, manufacturing, market, media, products, property, research, revenue, securities, technology, video